COR

Cencora, Inc.

Fundamental data last updated:August 16, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Distribution

Exchange

NYSE

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

 


VALUATION

P/E

22.79

Market Cap ($M USD)

$58.09B

Forward P/E

9.62

PEG

0.07

PRICE TO SALES

0.18

PRICE TO BOOK

17.09

EV / EBITDA

13.66

5-Year Average P/E

Free Cash Flow Yield

2.68%

DCF Value

$703.12

Graham Number

$71.75

Price to FCF

37.28

EV to FCF

43.79

Earnings Yield

4.39%

FCF Yield

2.68%

DIVIDEND

Yield

0.79%

Annual Payout

$2.35

Payout Ratio

18.01%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$13.10

Next Year EPS Growth Estimate

$31.04

Next Year Revenue Growth Estimate

$384.62B

Return on Equity (ROE)

115.93%

FREE CASH FLOW

Operating Margin

1.28%

Debt-to-Equity

7.13

Piotroski F-Score

5

Altman Z-Score

4.73

Return on Invested Capital (ROIC)

16.46%

Current Ratio

0.95

Quick Ratio

0.59

Net Debt to EBITDA

2.03

Interest Coverage

8.86

Gross Profit margin

3.47%

FCF PER SHARE

$8.01

REVENUE PER SHARE

$1689.48

Gainseekers Quantitative Analysis

Summary

Cencora, Inc. appears to be a classic case of market mispricing. With a DCF value significantly higher than recent pricing, the stock seems undervalued. The Forward P/E ratio suggests robust growth expectations, while a high Altman Z-score indicates financial stability. However, the earnings yield is modest, hinting at limited immediate returns. Despite these concerns, the company’s valuation metrics suggest a compelling opportunity for investors seeking growth at a reasonable price.

AI Exposure / Tech Reliance

Operating in the Medical Distribution industry, Cencora is strategically positioned to leverage AI and tech advancements. The healthcare sector is ripe for innovation, and companies like Cencora can capitalize on AI-driven efficiencies. Their ability to integrate technology into distribution processes will be crucial for maintaining a competitive edge.

The Bull Case

For the discerning GARP investor, Cencora offers a tantalizing proposition. A stellar ROIC of 16.46% underscores its capital efficiency, while a Piotroski F-Score of 5 indicates moderate financial health. The company's ability to generate free cash flow, albeit with a modest yield, suggests underlying strength. Despite slim margins, the firm's operational prowess could translate into long-term pricing power.

The Bear Case

Yet, Cencora is not without its flaws. The Price/Book ratio is alarmingly high, signaling potential overvaluation. A low gross profit margin raises questions about its cost structure and competitive pressures. Additionally, the stock's proximity to its 52-week high suggests technical overextension. These factors could pose significant risks to investors banking on sustained growth.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$378.57

Institutional Ownership %

1-Year Beta

0.58

Insider Buying % (6 Mo)

Distance to 52-Week High

26.46%

Distance to 52-Week Low

18.00%

EARNINGS SURPRISE %

-1.45%

50-DAY SMA

$279.08

200-DAY SMA

$324.33

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.